Solitomab

Source: Wikipedia, the free encyclopedia.
Solitomab
EpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII

Solitomab (

EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.[1][2][3]

Mechanism of action

A BiTE linking a T cell to a tumor cell.

Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert

MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.[1][4] This action mimics physiological processes observed during T cell attacks against tumor cells.[4]

References

  1. ^ a b Helwick C (June 2008). "Novel BiTE antibody mediates contact between T cells and cancer cells". Oncology NEWS International. 17 (6).
  2. ^ Clinical trial number NCT00635596 for "Phase I Study of MT110 in Colorectal Cancer (CRC), Gastrointestinal (GI) and Lung Cancer (MT110-101)" at ClinicalTrials.gov
  3. S2CID 25568468
    .
  4. ^ a b "BiTE Antibody Platform". Micromet Inc.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Solitomab&oldid=1138423089"